Agenus Surges 83% On $340 Million Financing: The Road To A 2030 Breakthrough

Agenus shifts to BOT+BAL in neoadjuvant MSS colon cancer; $85M raise extends runway to 2031. Click here to read this latest analysis of AGEN stock.

Thesis: BOT+BAL in neoadjuvant MSS colon cancer Agenus Inc. (AGEN) is now making a pretty clear strategic pivot this year. They want to fully prioritise BOT+BAL in the neoadjuvant MSS colon cancer setting and take a step away from their Agenus Inc. (AGEN) is now making a pretty clear strategic pivot this year. They want to fully prioritise BOT+BAL in the neoadjuvant MSS colon cancer setting and take a step away from their Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.